Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions

Chemistry and Biology

Volumn 22, Issue 6, 2015, Pages 689-703

  Laraia, Luca ^a,b   McKenzie, Grahame ^b   Spring, David R ^a   Venkitaraman, Ashok R ^b   Huggins, David J ^a,b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MOLECULAR LIBRARY; PROTEIN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; DRUG INDUSTRY; ENZYME ACTIVE SITE; GENETIC CONSERVATION; HUMAN; HUMAN GENOME; IN VITRO STUDY; MACHINE LEARNING; MACROMOLECULE; MICROTUBULE ASSEMBLY; MOLECULAR LIBRARY; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMISTRY; METABOLISM; MOLECULAR DOCKING; SIGNAL TRANSDUCTION;

APOPTOSIS; BINDING SITES; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEINS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84934912798     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2015.04.019     Document Type: Review

References (167)

1. N. Abdel-Rahman, A. Martinez-Arias, and T.L. Blundell Probing the druggability of protein-protein interactions: targeting the Notch1 receptor ankyrin domain using a fragment-based approach Biochem. Soc. Trans. 39 2011 1327 1333
2. F.J. Adrián, Q. Ding, T. Sim, A. Velentza, C. Sloan, Y. Liu, G. Zhang, W. Hur, S. Ding, and P. Manley Allosteric inhibitors of Bcr-abl-dependent cell proliferation Nat. Chem. Biol. 2 2006 95 102
3. C. Aguirre, T. Ten Brink, O. Walker, F. Guilliere, D. Davesne, and I. Krimm BcL-xL conformational changes upon fragment binding revealed by NMR PLoS One 8 2013 e64400
4. M. Ahern, C. Reid, T. Gordon, M. McCredie, P. Brooks, and M. Jones Does colchicine work? The results of the first controlled study in acute gout Aust. N. Z. J. Med. 17 1987 301 304
5. A.I. Archakov, V.M. Govorun, A.V. Dubanov, Y.D. Ivanov, A.V. Veselovsky, P. Lewi, and P. Janssen Protein-protein interactions as a target for drugs in proteomics Proteomics 3 2003 380 391
6. M. Arkin, M. Glicksman, H. Fu, J. Havel, and Y. Du Inhibition of Protein-Protein Interactions: Non-cellular Assay Formats 2004 Eli Lilly and the National Center for Advancing Translational Sciences
7. M.R. Arkin, Y. Tang, and J.A. Wells Small-molecule inhibitors of protein-protein interactions: progressing toward the reality Chem. Biol. 21 2014 1102 1114
8. V. Azzarito, K. Long, N.S. Murphy, and A.J. Wilson Inhibition of [alpha]-helix-mediated protein-protein interactions using designed molecules Nat. Chem. 5 2013 161 173
9. J.B. Baell, and G.A. Holloway New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 53 2010 2719 2740
10. N.N. Batada, L.D. Hurst, and M. Tyers Evolutionary and physiological importance of hub proteins PLoS Comput. Biol. 2 2006 e88
11. K.A. Beauchamp, Y.-S. Lin, R. Das, and V.S. Pande Are protein force fields getting better? A systematic benchmark on 524 diverse NMR measurements J. Chem. Theor. Comput. 8 2012 1409 1414
12. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The Protein Data Bank Nucleic Acids Res. 28 2000 235 242
13. A. Bernini, L. Henrici De Angelis, E. Morandi, O. Spiga, A. Santucci, M. Assfalg, H. Molinari, S. Pillozzi, A. Arcangeli, and N. Niccolai Searching for protein binding sites from molecular dynamics simulations and paramagnetic fragment-based NMR studies Biochim. Biophys. Acta 1844 2014 561 566
14. T. Beuming, Y. Che, R. Abel, B. Kim, V. Shanmugasundaram, and W. Sherman Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization Proteins 80 2012 871 883
15. H.E. Blackwell, and R.H. Grubbs Highly efficient synthesis of covalently cross-linked peptide helices by ring-closing metathesis Angew. Chem. Int. Ed. Engl. 37 1998 3281 3284
16. A.A. Bogan, and K.S. Thorn Anatomy of hot spots in protein interfaces J. Mol. Biol. 280 1998 1 9
17. R.T. Bradshaw, B.H. Patel, E.W. Tate, R.J. Leatherbarrow, and I.R. Gould Comparing experimental and computational alanine scanning techniques for probing a prototypical protein-protein interaction Protein Eng. Des. Sel. 24 2011 197 207
18. A.C. Braisted, J.D. Oslob, W.L. Delano, J. Hyde, R.S. McDowell, N. Waal, C. Yu, M.R. Arkin, and B.C. Raimundo Discovery of a potent small molecule IL-2 inhibitor through fragment assembly J. Am. Chem. Soc. 125 2003 3714 3715
19. B. Breiten, M.R. Lockett, W. Sherman, S. Fujita, M.H. Al-Sayah, H. Lange, C.M. Bowers, A. Heroux, G. Krilov, and G.M. Whitesides Water networks contribute to enthalpy/entropy compensation in protein-ligand binding J. Am. Chem. Soc. 135 2013 15579 15584
20. R. Brenke, D. Kozakov, G.-Y. Chuang, D. Beglov, D. Hall, M.R. Landon, C. Mattos, and S. Vajda Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques Bioinformatics 25 2009 621 627
21. S.P. Brown, and P.J. Hajduk Effects of conformational dynamics on predicted protein druggability ChemMedChem 1 2006 70 72
22. B.N. Bullock, A.L. Jochim, and P.S. Arora Assessing helical protein interfaces for inhibitor design J. Am. Chem. Soc. 133 2011 14220 14223
23. Y.S. Chang, B. Graves, V. Guerlavais, C. Tovar, K. Packman, K.-H. To, K.A. Olson, K. Kesavan, P. Gangurde, and A. Mukherjee Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy Proc. Natl. Acad. Sci. USA 110 2013 E3445 E3454
24. H. Chen, and H.X. Zhou Prediction of interface residues in protein-protein complexes by a consensus neural network method: test against NMR data Proteins 61 2005 21 35
25. A.C. Cheng, R.G. Coleman, K.T. Smyth, Q. Cao, P. Soulard, D.R. Caffrey, A.C. Salzberg, and E.S. Huang Structure-based maximal affinity model predicts small-molecule druggability Nat. Biotechnol. 25 2007 71 75
26. L.S. Cheng, R.E. Amaro, D. Xu, W.W. Li, P.W. Arzberger, and J.A. McCammon Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase J. Med. Chem. 51 2008 3878 3894
27. C.W. Chung, A.W. Dean, J.M. Woolven, and P. Bamborough Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery J. Med. Chem. 55 2012 576 586
28. T. Clackson, and J.A. Wells A hot spot of binding energy in a hormone-receptor interface Science 267 1995 383 386
29. A.G. Coyne, D.E. Scott, and C. Abell Drugging challenging targets using fragment-based approaches Curr. Opin. Chem. Biol. 14 2010 299 307
30. C.G. Cummings, and A.D. Hamilton Disrupting protein-protein interactions with non-peptidic, small molecule α-helix mimetics Curr. Opin. Chem. Biol. 14 2010 341 346
31. K.L. Damm, and H.A. Carlson Exploring experimental sources of multiple protein conformations in structure-based drug design J. Am. Chem. Soc. 129 2007 8225 8235
32. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, and P.P. Zarrinkar Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1046 1051
33. O.N. Demerdash, M.D. Daily, and J.C. Mitchell Structure-based predictive models for allosteric hot spots PLoS Comput. Biol. 5 2009 e1000531
34. D.M. Dias, and A. Ciulli NMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexes Prog. Biophys. Mol. Biol. 116 2014 101 112
35. A. Dömling Small molecular weight protein-protein interaction antagonists - an insurmountable challenge? Curr. Opin. Chem. Biol. 12 2008 281 291
36. C.H. Douse, N. Vrielink, Z. Wenlin, E. Cota, and E.W. Tate Targeting a dynamic protein-protein interaction: fragment screening against the malaria myosin A motor complex ChemMedChem 10 2015 134 143
37. F.N. Edfeldt, R.H. Folmer, and A.L. Breeze Fragment screening to predict druggability (ligandability) and lead discovery success Drug Discov. Today 16 2011 284 287
38. T.J. Ewing, and I.D. Kuntz Critical evaluation of search algorithms for automated molecular docking and database screening J. Comput. Chem. 18 1997 1175 1189
39. L.D. Fader, E. Malenfant, M. Parisien, R.J. Carson, F. Bilodeau, S. Landry, M. Pesant, C. Brochu, S. Morin, and C. Chabot Discovery of BI 224436, a Non-Catalytic Site Integrase Inhibitor (NCINI) of HIV-1 ACS Med. Chem. Lett. 5 2014 422 427
40. H. Fan, J.J. Irwin, B.M. Webb, G. Klebe, B.K. Shoichet, and A. Sali Molecular docking screens using comparative models of proteins J. Chem. Inf. Model. 49 2009 2512 2527
41. J. Fernández-Recio Prediction of protein binding sites and hot spots Wiley Interdiscip. Rev. Comput. Mol. Sci. 1 2011 680 698
42. J. Fernandez-Recio, M. Totrov, and R. Abagyan Identification of protein-protein interaction sites from docking energy landscapes J. Mol. Biol. 335 2004 843 865
43. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. Morse, T. Keates, T.T. Hickman, and I. Felletar Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
44. T. Fischer, K. Arunachalam, D. Bailey, V. Mangual, S. Bakhru, R. Russo, D. Huang, M. Paczkowski, V. Lalchandani, and C. Ramachandra The binding interface database (BID): a compilation of amino acid hot spots in protein interfaces Bioinformatics 19 2003 1453 1454
45. C.D. Fjell, H. Jenssen, K. Hilpert, W.A. Cheung, N. Pante, R.E. Hancock, and A. Cherkasov Identification of novel antibacterial peptides by chemoinformatics and machine learning J. Med. Chem. 52 2009 2006 2015
46. T.J. Foster, A.D. MacKerell, and O. Guvench Balancing target flexibility and target denaturation in computational fragment-based inhibitor discovery J. Comput. Chem. 33 2012 1880 1891
47. E. Freire Can allosteric regulation be predicted from structure? Proc. Natl. Acad. Sci. USA 97 2000 11680 11682
48. D.C. Fry Protein-protein interactions as targets for small molecule drug discovery Biopolymers 84 2006 535 552
49. D. Fry, K.S. Huang, P. Di Lello, P. Mohr, K. Müller, S.S. So, T. Harada, M. Stahl, B. Vu, and H. Mauser Design of libraries targeting protein-protein interfaces ChemMedChem 8 2013 726 732
50. J.C. Fuller, N.J. Burgoyne, and R.M. Jackson Predicting druggable binding sites at the protein-protein interface Drug Discov. Today 14 2009 155 161
51. W.R. Galloway, A. Isidro-Llobet, and D.R. Spring Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules Nat. Commun. 1 2010 80
52. J. Gao, R. Ma, W. Wang, N. Wang, R. Sasaki, D. Snyderman, J. Wu, and K. Ruan Automated NMR fragment based screening identified a novel interface blocker to the LARG/RhoA complex PLoS One 9 2014 e88098
53. T. Geppert, S. Bauer, J.A. Hiss, E. Conrad, M. Reutlinger, P. Schneider, M. Weisel, B. Pfeiffer, K.H. Altmann, and Z. Waibler Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions Angew. Chem. Int. Ed. Engl. 51 2012 258 261
54. M.P. Gleeson, A. Hersey, D. Montanari, and J. Overington Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discov. 10 2011 197 208
55. H. Gohlke, C. Kiel, and D.A. Case Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes J. Mol. Biol. 330 2003 891 913
56. Y. Grigoryev Stapled peptide to enter human testing, but affinity questions remain Nat. Med. 19 2013 120
57. E. Guney, N. Tuncbag, O. Keskin, and A. Gursoy HotSprint: database of computational hot spots in protein interfaces Nucleic Acids Res. 36 2008 D662 D666
58. M. Gynther, K. Laine, J. Ropponen, J. Leppanen, A. Mannila, T. Nevalainen, J. Savolainen, T.T. Jarvinen, and J. Rautio Large neutral amino acid transporter enables brain drug delivery via prodrugs J. Med. Chem. 51 2008 932 936
59. M. Gynther, J. Ropponen, K. Laine, J. Leppanen, P. Haapakoski, L. Peura, T. Jarvinen, and J. Rautio Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats J. Med. Chem. 52 2009 3348 3353
60. M.K. Haider, and D.J. Huggins Combining solvent thermodynamic profiles with functionality maps of the Hsp90 binding site to predict the displacement of water molecules J. Chem. Inf. Model. 53 2013 2571 2586
61. P.J. Hajduk Fragment-based drug design: how big is too big? J. Med. Chem. 49 2006 6972 6976
62. P.J. Hajduk, J.R. Huth, and C. Tse Predicting protein druggability Drug Discov. Today 10 2005 1675 1682
63. T.A. Halgren Identifying and characterizing binding sites and assessing druggability J. Chem. Inf. Model. 49 2009 377 389
64. V. Hamon, J.M. Brunel, S. Combes, M.J. Basse, P. Roche, and X. Morelli 2P2Ichem: focused chemical libraries dedicated to orthosteric modulation of protein-protein interactions Med. Chem. Commun. 4 2013 797 809
65. J.C. Harris, R.D. Hill, D.W. Sheppard, M.J. Slater, and P.F. Stouten The design and application of target-focused compound libraries Comb. Chem. High Throughput Screen. 14 2011 521 531
66. A.P. Higueruelo, A. Schreyer, G.R.J. Bickerton, W.R. Pitt, C.R. Groom, and T.L. Blundell Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database Chem. Biol. Drug Des. 74 2009 457 467
67. A.P. Higueruelo, H. Jubb, and T.L. Blundell Protein-protein interactions as druggable targets: recent technological advances Curr. Opin. Pharmacol. 13 2013 791 796
68. R.S. Holvey, E. Valkov, D. Neal, M. Stewart, and C. Abell Selective targeting of the TPX2 site of importin-α using fragment-based ligand design ChemMedChem 2015 10.1002/cmdc.201500014 Published online April 20, 2015
69. L. Hood, and R.M. Perlmutter The impact of systems approaches on biological problems in drug discovery Nat. Biotechnol. 22 2004 1215 1217
70. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
71. A.L. Hopkins, C.R. Groom, and A. Alex Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
72. A.L. Hopkins, G.M. Keserü, P.D. Leeson, D.C. Rees, and C.H. Reynolds The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discov. 13 2014 105 121
73. D.J. Huggins, and M.C. Payne Assessing the accuracy of inhomogeneous fluid solvation theory in predicting hydration free energies of simple solutes J. Phys. Chem. B 117 2013 8232 8244
74. D.J. Huggins, G. McKenzie, D. Robinson, A. Narváez, B. Hardwick, M. Roberts-Thomson, A. Venkitaraman, G. Grant, and M. Payne Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation PLoS Comput. Biol. 6 2010 10.1371/journal.pcbi.1000880
75. D.J. Huggins, A.R. Venkitaraman, and D.R. Spring Rational methods for the selection of diverse screening compounds ACS Chem. Biol. 6 2011 208 217
76. A.W. Hung, A. Ramek, Y. Wang, T. Kaya, J.A. Wilson, P.A. Clemons, and D.W. Young Route to three-dimensional fragments using diversity-oriented synthesis Proc. Natl. Acad. Sci. USA 108 2011 6799 6804
77. J. Janin Protein-protein docking tested in blind predictions: the CAPRI experiment Mol. Biosyst. 6 2010 2351 2362
78. D.K. Johnson, and J. Karanicolas Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface PLoS Comput. Biol. 9 2013 e1002951
79. T.W. Johnson, K.R. Dress, and M. Edwards Using the Golden Triangle to optimize clearance and oral absorption Bioorg. Med. Chem. Lett. 19 2009 5560 5564
80. G. Jones, P. Willett, and R.C. Glen Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation J. Mol. Biol. 245 1995 43 53
81. R.A. Jose, A. Voet, K. Broos, A.J. Jakobi, G. Bruylants, B. Egle, K.Y. Zhang, M. De Maeyer, H. Deckmyn, and W.M. De Borggraeve An integrated fragment based screening approach for the discovery of small molecule modulators of the VWF-GPIbalpha interaction Chem. Commun. (Camb.) 48 2012 11349 11351
82. D.E. Kim, D. Chivian, and D. Baker Protein structure prediction and analysis using the Robetta server Nucleic Acids Res. 32 2004 W526 W531
83. D. Koes, K. Khoury, Y. Huang, W. Wang, M. Bista, G.M. Popowicz, S. Wolf, T.A. Holak, A. Dömling, and C.J. Camacho Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists PLoS one 7 2012 e32839
84. O. Korb, T.S. Olsson, S.J. Bowden, R.J. Hall, M.L. Verdonk, J.W. Liebeschuetz, and J.C. Cole Potential and limitations of ensemble docking J. Chem. Inf. Model. 52 2012 1262 1274
85. P.K. Kreeger, and D.A. Lauffenburger Cancer systems biology: a network modeling perspective Carcinogenesis 31 2010 2 8
86. D.M. Krüger, and H. Gohlke DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein-protein interactions Nucleic Acids Res. 38 2010 W480 W486
87. M.A. Kuenemann, L.M. Bourbon, C.M. Labbe, B.O. Villoutreix, and O. Sperandio Which three-dimensional characteristics make efficient inhibitors of protein-protein interactions? J. Chem. Inf. Model. 54 2014 3067 3079
88. C.M. Labbé, G. Laconde, M.A. Kuenemann, B.O. Villoutreix, and O. Sperandio iPPI-DB: A manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions Drug Discov. Today 18 2013 958 968
89. M.R. Landon, D.R. Lancia, J. Yu, S.C. Thiel, and S. Vajda Identification of hot spots within druggable binding regions by computational solvent mapping of proteins J. Med. Chem. 50 2007 1231 1240
90. B.B. Lao, I. Grishagin, H. Mesallati, T.F. Brewer, B.Z. Olenyuk, and P.S. Arora In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics Proc. Natl. Acad. Sci. USA 111 2014 7531 7536
91. L. Laraia, and D.R. Spring Chemical library screening approaches to aid the design of protein-protein inhibitors G. Zinzalla, Understanding and Exploiting Protein-Protein Interactions as Drug Targets 2013 Future Science 32 45
92. Y.H. Lau, P. de Andrade, S.-T. Quah, M. Rossmann, L. Laraia, N. Sköld, T.J. Sum, P.J. Rowling, T.L. Joseph, and C. Verma Functionalised staple linkages for modulating the cellular activity of stapled peptides Chem. Sci. 5 2014 1804 1809
93. B. Leader, Q.J. Baca, and D.E. Golan Protein therapeutics: a summary and pharmacological classification Nat. Rev. Drug Discov. 7 2008 21 39
94. J.H. Lee, Q. Zhang, S. Jo, S.C. Chai, M. Oh, W. Im, H. Lu, and H.S. Lim Novel pyrrolopyrimidine-based alpha-helix mimetics: cell-permeable inhibitors of protein-protein interactions J. Am. Chem. Soc. 133 2011 676 679
95. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890
96. K.W. Lexa, and H.A. Carlson Full protein flexibility is essential for proper hot-spot mapping J. Am. Chem. Soc. 133 2010 200 202
97. K.W. Lexa, and H.A. Carlson Improving protocols for protein mapping through proper comparison to crystallography data J. Chem. Inf. Model. 53 2013 391 402
98. Z. Li, and T. Lazaridis Thermodynamics of buried water clusters at a protein-ligand binding interface J. Phys. Chem. B 110 2006 1464 1475
99. R.M. Liskamp, D.T. Rijkers, and S.E. Bakker Bioactive macrocyclic peptides and peptide mimics F. Diederich, P.J. Stang, R.R. Tykwinski, Modern Supramolecular Chemistry: Strategies for Macrocycle Synthesis 2008 Wiley-VCH 1 27
100. T. Liu, Y. Lin, X. Wen, R.N. Jorissen, and M.K. Gilson BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 35 2007 D198 D201
101. G. Lund, S. Dudkin, D. Borkin, W. Ni, J. Grembecka, and T. Cierpicki Inhibition of CDC25B phosphatase through disruption of protein-protein interaction ACS Chem. Biol. 10 2015 390 394
102. L.A. Marcaurelle, C. Johannes, D. Yohannes, B.P. Tillotson, and D. Mann Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2 Bioorg. Med. Chem. Lett. 19 2009 2500 2503
103. S.A. Martins, M.A. Perez, I.S. Moreira, S.r.F. Sousa, M. Ramos, and P. Fernandes Computational alanine scanning mutagenesis: MM-PBSA vs TI J. Chem. Theor. Comput. 9 2013 1311 1319
104. K. Matsuno, Y. Masuda, Y. Uehara, H. Sato, A. Muroya, O. Takahashi, T. Yokotagawa, T. Furuya, T. Okawara, and M. Otsuka Identification of a new series of STAT3 inhibitors by virtual screening ACS Med. Chem. Lett. 1 2010 371 375
105. T. Maurer, L.S. Garrenton, A. Oh, K. Pitts, D.J. Anderson, N.J. Skelton, B.P. Fauber, B. Pan, S. Malek, and D. Stokoe Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity Proc. Natl. Acad. Sci. USA 109 2012 5299 5304
106. A. Metz, C. Pfleger, H. Kopitz, S. Pfeiffer-Marek, K.H. Baringhaus, and H. Gohlke Hot spots and transient pockets: predicting the determinants of small-molecule binding to a protein-protein interface J. Chem. Inf. Model. 52 2012 120 133
107. N. Miyashita, J.E. Straub, D. Thirumalai, and Y. Sugita Transmembrane structures of amyloid precursor protein dimer predicted by replica-exchange molecular dynamics simulations J. Am. Chem. Soc. 131 2009 3438 3439
108. R.E. Moellering, M. Cornejo, T.N. Davis, C. Del Bianco, J.C. Aster, S.C. Blacklow, A.L. Kung, D.G. Gilliland, G.L. Verdine, and J.E. Bradner Direct inhibition of the NOTCH transcription factor complex Nature 462 2009 182 188
109. M. Molzan, M. Weyand, R. Rose, and C. Ottmann Structural insights of the MLF1/14-3-3 interaction FEBS J. 279 2012 563 571
110. C.D. Moore, H. Wu, B. Bolanos, S. Bergqvist, A. Brooun, T. Pauly, and D. Nowlin Structural and biophysical characterization of XIAP BIR3 G306E mutant: insights in protein dynamics and application for fragment-based drug design Chem. Biol. Drug Des. 74 2009 212 223
111. I.S. Moreira, P.A. Fernandes, and M.J. Ramos Computational alanine scanning mutagenesis - an improved methodological approach J. Comput. Chem. 28 2007 644 654
112. X. Morelli, R. Bourgeas, and P. Roche Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I) Curr. Opin. Chem. Biol. 15 2011 475 481
113. A.D. Morley, A. Pugliese, K. Birchall, J. Bower, P. Brennan, N. Brown, T. Chapman, M. Drysdale, I.H. Gilbert, and S. Hoelder Fragment-based hit identification: thinking in 3D Drug Discov. Today 18 2013 1221 1227
114. A. Mullard Protein-protein interaction inhibitors get into the groove Nat. Rev. Drug Discov. 11 2012 173 175
115. N.S. Murphy, P. Prabhakaran, V. Azzarito, J.P. Plante, M.J. Hardie, C.A. Kilner, S.L. Warriner, and A.J. Wilson Solid-phase methodology for synthesis of O-alkylated aromatic oligoamide inhibitors of α-helix-mediated protein-protein interactions Chem-Eur J. 19 2013 5546 5550
116. S.S. Negi, and W. Braun Statistical analysis of physical-chemical properties and prediction of protein-protein interfaces J. Mol. Model. 13 2007 1157 1167
117. A. Neugebauer, R.W. Hartmann, and C.D. Klein Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods J. Med. Chem. 50 2007 4665 4668
118. 3H] vinblastine in tumor and host tissues of Nb rats bearing a transplantable lymphoma which is highly sensitive to the alkaloid Cancer Res. 37 1977 1455 1460
119. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M. Bruncko, T.L. Deckwerth, J. Dinges, and P.J. Hajduk An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
120. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
121. L. Pagliaro, J. Felding, K. Audouze, S.J. Nielsen, R.B. Terry, C. Krog-Jensen, and S. Butcher Emerging classes of protein-protein interaction inhibitors and new tools for their development Curr. Opin. Chem. Biol. 8 2004 442 449
122. M.K. Parai, D.J. Huggins, H. Cao, M.N.L. Nalam, A. Ali, C.A. Schiffer, B. Tidor, and T.M. Rana Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance J. Med. Chem. 55 2012 6328 6341
123. J.D. Patrone, J.P. Kennedy, A.O. Frank, M.D. Feldkamp, B. Vangamudi, N.F. Pelz, O.W. Rossanese, A.G. Waterson, W.J. Chazin, and S.W. Fesik Discovery of protein-protein interaction inhibitors of replication protein A ACS Med. Chem. Lett. 4 2013 601 605
124. S.J. Pfaff, M.S. Chimenti, M.J. Kelly, and M.R. Arkin Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions Methods Mol. Biol. 1278 2015 587 613
125. S. Pitre, F. Dehne, A. Chan, J. Cheetham, A. Duong, A. Emili, M. Gebbia, J. Greenblatt, M. Jessulat, and N. Krogan PIPE: a protein-protein interaction prediction engine based on the re-occurring short polypeptide sequences between known interacting protein pairs BMC Bioinformatics 7 2006 365
126. Y. Pommier, and C. Marchand Interfacial inhibitors: targeting macromolecular complexes Nat. Rev. Drug Discov. 11 2012 25 36
127. E.P. Raman, W. Yu, O. Guvench, and A.D. MacKerell Jr. Reproducing crystal binding modes of ligand functional groups using Site-Identification by Ligand Competitive Saturation (SILCS) simulations J. Chem. Inf. Model. 51 2011 877 896
128. C. Reynès, H. Host, A.-C. Camproux, G. Laconde, F. Leroux, A. Mazars, B. Deprez, R. Fahraeus, B.O. Villoutreix, and O. Sperandio Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods PLoS Comput. Biol. 6 2010 e1000695
129. N. Rhodes, D.A. Heerding, D.R. Duckett, D.J. Eberwein, V.B. Knick, T.J. Lansing, R.T. McConnell, T.M. Gilmer, S.-Y. Zhang, and K. Robell Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity Cancer Res. 68 2008 2366 2374
130. S. Riniker, C.D. Christ, H.S. Hansen, P.H. Hünenberger, C. Oostenbrink, D. Steiner, and W.F. van Gunsteren Calculation of relative free energies for ligand-protein binding, solvation, and conformational transitions using the GROMOS software J. Phys. Chem. B 115 2011 13570 13577
131. P. Ripphausen, B. Nisius, L. Peltason, and J. Bajorath Quo vadis, virtual screening? A comprehensive survey of prospective applications J. Med. Chem. 53 2010 8461 8467
132. P.D. Roepe A peptide needle in a signaling haystack Nat. Genet. 27 2001 6 7
133. J. Rouhana, F. Hoh, S. Estaran, C. Henriquet, Y. Boublik, A. Kerkour, R. Trouillard, J. Martinez, M. Pugniere, and A. Padilla Fragment-based identification of a locus in the Sec7 domain of Arno for the design of protein-protein interaction inhibitors J. Med. Chem. 56 2013 8497 8511
134. H. Ruffner, A. Bauer, and T. Bouwmeester Human protein-protein interaction networks and the value for drug discovery Drug Discov. Today 12 2007 709 716
135. J.G. Sathish, S. Sethu, M.-C. Bielsky, L. de Haan, N.S. French, K. Govindappa, J. Green, C.E. Griffiths, S. Holgate, and D. Jones Challenges and approaches for the development of safer immunomodulatory biologics Nat. Rev. Drug Discov. 12 2013 306 324
136. J.R. Schames, R.H. Henchman, J.S. Siegel, C.A. Sotriffer, H. Ni, and J.A. McCammon Discovery of a novel binding trench in HIV integrase J. Med. Chem. 47 2004 1879 1881
137. G. Schneider Designing the molecular future J. Comput. Aided Mol. Des. 26 2012 115 120
138. T. Scior, A. Bender, G. Tresadern, J.L. Medina-Franco, K. Martínez-Mayorga, T. Langer, K. Cuanalo-Contreras, and D.K. Agrafiotis Recognizing pitfalls in virtual screening: a critical review J. Chem. Inf. Model. 52 2012 867 881
139. M.S. Scott, and G.J. Barton Probabilistic prediction and ranking of human protein-protein interactions BMC Bioinformatics 8 2007 239
140. D.E. Scott, M.T. Ehebauer, T. Pukala, M. Marsh, T.L. Blundell, A.R. Venkitaraman, C. Abell, and M. Hyvönen Using a fragment-based approach to target protein-protein interactions ChemBioChem 14 2013 332 342
141. A. Shaginian, L.R. Whitby, S. Hong, I. Hwang, B. Farooqi, M. Searcey, J. Chen, P.K. Vogt, and D.L. Boger Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions J. Am. Chem. Soc. 131 2009 5564 5572
142. R.P. Sheridan, V.N. Maiorov, M.K. Holloway, W.D. Cornell, and Y.-D. Gao Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank J. Chem. Inf. Model. 50 2010 2029 2040
143. Y.S. Tan, P. ͆ledź, S. Lang, C.J. Stubbs, D.R. Spring, C. Abell, and R.B. Best Using ligand-mapping simulations to design a ligand selectively targeting a cryptic surface pocket of polo-like kinase 1 Angew. Chem. Int. Ed. Engl. 124 2012 10225 10228
144. S.J. Teague, A.M. Davis, P.D. Leeson, and T. Oprea The design of leadlike combinatorial libraries Angew. Chem. Int. Ed. Engl. 38 1999 3743 3748
145. K.S. Thorn, and A.A. Bogan ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions Bioinformatics 17 2001 284 285
146. M. Totrov, and R. Abagyan Flexible ligand docking to multiple receptor conformations: a practical alternative Curr. Opin. Struct. Biol. 18 2008 178 184
147. C. Tse, A.R. Shoemaker, J. Adickes, M.G. Anderson, J. Chen, S. Jin, E.F. Johnson, K.C. Marsh, M.J. Mitten, and P. Nimmer ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 68 2008 3421 3428
148. N. Tuncbag, A. Gursoy, and O. Keskin Identification of computational hot spots in protein interfaces: combining solvent accessibility and inter-residue potentials improves the accuracy Bioinformatics 25 2009 1513 1520
149. N. Tuncbag, O. Keskin, and A. Gursoy HotPoint: hot spot prediction server for protein interfaces Nucleic Acids Res. 38 2010 W402 W406
150. N. Tuncbag, O. Keskin, R. Nussinov, and A. Gursoy Fast and accurate modeling of protein-protein interactions by combining template-interface-based docking with flexible refinement Proteins 80 2012 1239 1249
151. E. Valkov, T. Sharpe, M. Marsh, S. Greive, and M. Hyvonen Targeting protein-protein interactions and fragment-based drug discovery Top. Curr. Chem. 317 2012 145 179
152. I. Van Molle, A. Thomann, D.L. Buckley, E.C. So, S. Lang, C.M. Crews, and A. Ciulli Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1alpha protein-protein interface Chem. Biol. 19 2012 1300 1312
153. B.O. Villoutreix, M.A. Kuenemann, J.L. Poyet, H. Bruzzoni-Giovanelli, C. Labbe, D. Lagorce, O. Sperandio, and M.A. Miteva Drug-like protein-protein interaction modulators: challenges and opportunities for drug discovery and chemical biology Mol. Inform. 33 2014 414 437
154. B. Vu, P. Wovkulich, G. Pizzolato, A. Lovey, Q. Ding, N. Jiang, J.-J. Liu, C. Zhao, K. Glenn, and Y. Wen Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development ACS Med. Chem. Lett. 4 2013 466 469
155. L.D. Walensky, and G.H. Bird Hydrocarbon-stapled peptides: principles, practice, and progress J. Med. Chem. 57 2014 6275 6288
156. L. Wang, Y. Deng, J.L. Knight, Y. Wu, B. Kim, W. Sherman, J.C. Shelley, T. Lin, and R. Abel Modeling local structural rearrangements using FEP/REST: application to relative binding affinity predictions of CDK2 inhibitors J. Chem. Theor. Comput. 9 2013 1282 1293
157. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009
158. L.R. Whitby, and D.L. Boger Comprehensive peptidomimetic libraries targeting protein-protein interactions Acc. Chem. Res. 45 2012 1698 1709
159. C.G. Wilson, and M.R. Arkin Probing structural adaptivity at PPI interfaces with small molecules Drug Discov. Today 10 2013 e501 e508
160. A. Winter, A.P. Higueruelo, M. Marsh, A. Sigurdardottir, W.R. Pitt, and T.L. Blundell Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery Q. Rev. Biophys. 45 2012 383 426
161. X. Xu, C. Leo, Y. Jang, E. Chan, D. Padilla, B.C. Huang, T. Lin, T. Gururaja, Y. Hitoshi, and J.B. Lorens Dominant effector genetics in mammalian cells Nat. Genet. 27 2001 23 29
162. M.A. Yildirim, K.I. Goh, M.E. Cusick, A.L. Barabasi, and M. Vidal Drug-target network Nat. Biotechnol. 25 2007 1119 1126
163. Z. Yin, L.R. Whittell, Y. Wang, S. Jergic, M. Liu, E.J. Harry, N.E. Dixon, J.L. Beck, M.J. Kelso, and A.J. Oakley Discovery of lead compounds targeting the bacterial sliding clamp using a fragment-based approach J. Med. Chem. 57 2014 2799 2806
164. B.S. Zerbe, D.R. Hall, S. Vajda, A. Whitty, and D. Kozakov Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces J. Chem. Inf. Model. 52 2012 2236 2244
165. J. Zhang, F.J. Adrián, W. Jahnke, S.W. Cowan-Jacob, A.G. Li, R.E. Iacob, T. Sim, J. Powers, C. Dierks, and F. Sun Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 2010 501 506
166. M. Zhong, T.R. Gadek, M. Bui, W. Shen, J. Burnier, K.J. Barr, E.J. Hanan, J.D. Oslob, C.H. Yu, and J. Zhu Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye ACS Med. Chem. Lett. 3 2012 203 206
167. G. Zinzalla, and D.E. Thurston Targeting protein-protein interactions for therapeutic intervention: a challenge for the future Future Med. Chem. 1 2009 65 93